Ferraiolo B L, Fuller G B, Burnett B, Chan E
Department of Pharmacological Sciences, Genentech, Inc., South San Francisco, California 94080.
J Biol Response Mod. 1988 Apr;7(2):115-22.
The pharmacokinetics of recombinant human interferon-gamma (rIFN-gamma) were studied in rhesus monkeys. Intravenous administration of 0.1 mg/kg yielded half-lives of 12.3-13.4 min and 130 min. Clearance after intravenous administration was 18.7 ml/min/kg, and the steady-state volume of distribution (Vdss) was 510 ml/kg. The peak serum concentrations after intramuscular and subcutaneous administration of 0.25 mg/kg rIFN-gamma were 50.7 and 52.3 ng/ml, respectively. The time to reach the peak serum concentration was 480 min for both routes. The mean bioavailabilities after intramuscular and subcutaneous administration were 109 and 90%, respectively. Intravenous administration of 0.25 mg/kg rIFN-gamma resulted in no significant change in the clearance, half-life, or Vdss, suggesting that the kinetics of rIFN-gamma are linear over the range of doses tested. Nearly all of the animals developed antibodies to rIFN-gamma after three doses. The presence of nonneutralizing antibodies to rIFN-gamma had no discernible effect on the calculated pharmacokinetic parameters.
在恒河猴身上研究了重组人干扰素-γ(rIFN-γ)的药代动力学。静脉注射0.1mg/kg时,半衰期为12.3 - 13.4分钟和130分钟。静脉注射后的清除率为18.7ml/分钟/千克,稳态分布容积(Vdss)为510ml/千克。肌肉注射和皮下注射0.25mg/kg rIFN-γ后的血清峰值浓度分别为50.7和52.3ng/ml。两种给药途径达到血清峰值浓度的时间均为480分钟。肌肉注射和皮下注射后的平均生物利用度分别为109%和90%。静脉注射0.25mg/kg rIFN-γ后,清除率、半衰期或Vdss均无显著变化,这表明在测试剂量范围内rIFN-γ的动力学呈线性。几乎所有动物在三次给药后都产生了针对rIFN-γ的抗体。rIFN-γ非中和抗体的存在对计算出的药代动力学参数没有明显影响。